Market Summary
USD190.04-6.27
Delayedas of 03 Oct 2023, 03:36 pm-3.19%
SWAV Stock Price
SWAV RSI Chart
SWAV Valuation
SWAV Price/Sales (Trailing)
SWAV Profitability
SWAV Fundamentals
SWAV Revenue
SWAV Earnings
Price Action
52 Week Range
172.50320.54
(Low)(High)
Last 7 days
1.0%
Last 30 days
-11.7%
Last 90 days
-29.6%
Trailing 12 Months
-29.4%
SWAV Financial Health
SWAV Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SWAV
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-26 | Zacharias Isaac | sold | -768,480 | 192 | -4,000 | president, cco |
2023-09-20 | WATKINS FRANK T | acquired | 10,248 | 3.416 | 3,000 | - |
2023-09-20 | WATKINS FRANK T | sold | -627,690 | 209 | -3,000 | - |
2023-09-15 | Godshall Douglas Evan | acquired | 34,160 | 3.416 | 10,000 | president & ceo |
2023-09-15 | Godshall Douglas Evan | sold | -2,128,610 | 212 | -10,000 | president & ceo |
2023-09-11 | Zacharias Isaac | sold (taxes) | -123,949 | 229 | -541 | president, cco |
2023-09-08 | Papiernik Antoine | sold | - | - | -21,926 | - |
2023-09-05 | Phung Trinh | sold (taxes) | -5,269 | 219 | -24.00 | vp, finance |
2023-08-29 | Phung Trinh | acquired | 17,080 | 3.416 | 5,000 | vp, finance |
2023-08-25 | Zacharias Isaac | sold | -819,920 | 204 | -4,000 | president, cco |
Which funds bought or sold SWAV recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -68.69 | -1,408,670 | 987,519 | -% |
2023-09-20 | BARCLAYS PLC | added | 11.33 | 4,724,000 | 14,867,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | added | 25.00 | 4,477 | 11,416 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -8.59 | 66,658 | 394,722 | 0.09% |
2023-08-23 | WOLVERINE TRADING, LLC | reduced | -17.18 | 51,872 | 551,872 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 9.9 | 978,068 | 3,168,050 | 0.03% |
2023-08-22 | COMERICA BANK | new | - | 49,000 | 49,000 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 184 | 3,441,000 | 4,694,000 | 0.04% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -1.58 | 2,882,400 | 12,639,100 | 0.02% |
2023-08-21 | BOKF, NA | reduced | -61.54 | -1,392 | 1,427 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Shockwave Medical
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 2.8% | 1,012,393 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 12.7% | 4,572,659 | SC 13G/A | |
| Jan 10, 2023 | vanguard group inc | 10.22% | 3,694,931 | SC 13G/A | |
| Jul 08, 2022 | blackrock inc. | 12.1% | 4,313,553 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 8.7% | 3,077,252 | SC 13G/A | |
| Feb 14, 2022 | gilder gagnon howe & co llc | 3.9% | 1,384,358 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.7% | 2,716,533 | SC 13G/A | |
| Jan 10, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Nov 09, 2021 | jpmorgan chase & co | 3.4% | 1,209,265 | SC 13G/A |
Recent SEC filings of Shockwave Medical
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 27, 2023 | 4 | Insider Trading | |
| Sep 25, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 21, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 8-K | Current Report | |
| Sep 06, 2023 | 4 | Insider Trading |
SWAV Fair Value
Loading...
Peers (Alternatives to Shockwave Medical)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 104.0B | 19.5B | -3.73% | 35.20% | 38.38 | 5.34 | 10.36% | 30.30% |
ISRG | 103.6B | 6.7B | -4.97% | 57.37% | 72.72 | 15.55 | 11.75% | -0.66% |
BSX | 76.4B | 13.4B | -1.51% | 36.35% | 83.74 | 5.7 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -7.43% | 16.56% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.1B | 5.7B | -9.43% | -16.28% | 30.27 | 7.43 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.1B | 937.8M | -9.65% | 25.86% | 313.94 | 9.75 | 16.30% | 250.21% |
SWAV | 7.2B | 616.6M | -11.74% | -29.40% | 29.51 | 11.67 | 69.52% | 343.68% |
GMED | 5.0B | 1.1B | -8.56% | -16.75% | 23.67 | 4.54 | 12.63% | 50.85% |
IRTC | 2.8B | 452.1M | -10.08% | -26.48% | -28.35 | 6.22 | 24.99% | 24.09% |
TNDM | 1.4B | 790.3M | -21.04% | -54.04% | -6.37 | 1.81 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.5B | 421.8M | -22.58% | 43.94% | -9.18 | 3.63 | 44.49% | -2.43% |
AVNS | 945.1M | 780.7M | -5.83% | -7.35% | -26.25 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 589.9M | 162.9M | -22.80% | -66.22% | -11.16 | 3.62 | 42.67% | 12.82% |
Shockwave Medical News
Returns for SWAV
Cumulative Returns on SWAV
37.8%
3-Year Cumulative Returns
Risks for SWAV
What is the probability of a big loss on SWAV?
98.3%
Probability that Shockwave Medical stock will be more than 20% underwater in next one year
74.7%
Probability that Shockwave Medical stock will be more than 30% underwater in next one year.
62.7%
Probability that Shockwave Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SWAV drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Shockwave Medical was unfortunately bought at previous high price.
Drawdowns
Financials for Shockwave Medical
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 10.7% | 616,587,000 | 557,168,000 | 489,733,000 | 429,890,000 | 363,715,000 | 298,877,000 | 237,146,000 | 175,679,000 | 130,114,000 | 84,492,000 | 67,789,000 | 59,385,000 | 51,128,000 | 50,854,000 | 42,927,000 | 33,676,000 | 25,943,000 | 18,210,000 | 12,263,000 | 9,601,333 | 7,202,000 |
| Gross Profit | 10.7% | 535,652,000 | 483,996,000 | 424,737,000 | 369,733,000 | 310,483,000 | 252,441,000 | 195,708,000 | 140,433,000 | 100,540,000 | 61,260,000 | 46,798,000 | 39,312,000 | 31,931,000 | 31,116,000 | 25,768,000 | 22,677,333 | 20,152,000 | 16,788,000 | 5,013,000 | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 107,133,333 | 97,636,000 | 87,538,667 | - | 71,313,333 | 66,976,000 | 65,424,000 | - | - | - |
| S&GA Expenses | 9.0% | 196,268,000 | 180,045,000 | 161,995,000 | 151,748,000 | 138,059,000 | 123,257,000 | 111,288,000 | 94,534,000 | 79,760,000 | 65,253,000 | 51,672,000 | 44,833,000 | 39,406,000 | 35,161,000 | 30,620,000 | 25,949,000 | 22,558,000 | 19,969,000 | 17,536,000 | 16,814,667 | 15,620,000 |
| R&D Expenses | 17.5% | 107,700,000 | 91,631,000 | 81,679,000 | 72,673,000 | 66,231,000 | 57,286,000 | 50,544,000 | 44,871,000 | 39,027,000 | 35,313,000 | 36,926,000 | 37,957,000 | 38,434,000 | 37,259,000 | 32,853,000 | 28,897,000 | 26,062,000 | 24,666,000 | 22,698,000 | 22,105,333 | 22,092,000 |
| EBITDA | -100.0% | - | 154,727,000 | 127,614,000 | 94,677,000 | 61,257,000 | 34,353,000 | -4,139,000 | -33,453,000 | -48,837,000 | -67,019,000 | -62,544,000 | -61,547,000 | -61,784,000 | -54,523,000 | -48,766,000 | -45,506,000 | -42,995,000 | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.28 | 0.26 | 0.22 | 0.17 | 0.11 | -0.02 | -0.19 | -0.38 | -0.79 | -0.92 | -1.04 | -1.21 | -1.07 | -1.14 | -1.35 | -1.66 | - | - | - | - |
| Interest Expenses | 22.5% | 2,699,000 | 2,203,000 | 1,900,000 | 1,222,000 | 1,071,000 | 1,085,000 | 1,100,000 | 1,098,000 | 1,247,000 | 1,235,000 | 1,200,000 | 1,095,000 | 1,032,000 | 976,000 | 944,000 | 931,000 | 838,000 | 628,000 | 401,000 | 288,000 | 116,000 |
| Earnings Before Taxes | 4.5% | 153,516,000 | 146,847,000 | 120,828,000 | 89,222,000 | 56,127,000 | 29,440,000 | -8,835,000 | -37,750,000 | -52,679,000 | -70,424,000 | -65,619,000 | -64,486,000 | -64,514,000 | -57,007,000 | -51,047,000 | -47,525,000 | -44,766,000 | -44,262,000 | -41,064,000 | -39,802,666 | -39,360,000 |
| EBT Margin | -100.0% | - | 0.26 | 0.25 | 0.21 | 0.15 | 0.10 | -0.04 | -0.21 | -0.40 | -0.83 | -0.97 | -1.09 | -1.26 | -1.12 | -1.19 | -1.41 | -1.73 | - | - | - | - |
| Net Income | 1.4% | 243,901,000 | 240,600,000 | 215,996,000 | 88,027,000 | 54,972,000 | 28,986,000 | -9,136,000 | -37,952,000 | -52,832,000 | -70,525,000 | -65,699,000 | -64,570,000 | -64,595,000 | -57,085,000 | -51,109,000 | -47,587,000 | -44,808,000 | -44,307,000 | -41,102,000 | -39,838,666 | -39,402,000 |
| Net Income Margin | -100.0% | - | 0.43 | 0.44 | 0.20 | 0.15 | 0.10 | -0.04 | -0.22 | -0.41 | -0.83 | -0.97 | -1.09 | -1.26 | -1.12 | -1.19 | -1.41 | -1.73 | - | - | - | - |
| Free Cashflow | -100.0% | - | 120,729,000 | 92,606,000 | 69,259,000 | 48,391,000 | 22,602,000 | 2,597,000 | -29,484,000 | -53,271,000 | -75,214,000 | -82,704,000 | -82,731,000 | -77,107,000 | -65,933,000 | -51,924,000 | -48,489,000 | -46,983,000 | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2017Q4 |
| Assets | 0.4% | 787 | 783 | 646 | 476 | 417 | 373 | 346 | 299 | 276 | 269 | 272 | 281 | 287 | 221 | 232 | 138 | 147 | 158 | 53.00 | 59.00 |
| Current Assets | -22.8% | 456 | 591 | 459 | 395 | 352 | 310 | 286 | 256 | 240 | 233 | 246 | 258 | 264 | 198 | 217 | 131 | 141 | 152 | 49.00 | 58.00 |
| Cash Equivalents | -49.6% | 141 | 281 | 157 | 128 | 100 | 66.00 | 91.00 | 93.00 | 86.00 | 58.00 | 52.00 | 215 | 218 | 123 | 140 | 39.00 | 42.00 | 138 | 40.00 | 52.00 |
| Inventory | 10.6% | 92.00 | 83.00 | 75.00 | 69.00 | 60.00 | 53.00 | 43.00 | 39.00 | 36.00 | 34.00 | 30.00 | 29.00 | 23.00 | 16.00 | 12.00 | 9.00 | 8.00 | 7.00 | 5.00 | 3.00 |
| Net PPE | 10.6% | 60.00 | 54.00 | 48.00 | 39.00 | 32.00 | 28.00 | 24.00 | 23.00 | 21.00 | 20.00 | 16.00 | 13.00 | 13.00 | 13.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 1.00 |
| Goodwill | 0% | 40.00 | 40.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Liabilities | -20.2% | 170 | 213 | 135 | 120 | 112 | 105 | 104 | 79.00 | 68.00 | 65.00 | 46.00 | 44.00 | 42.00 | 43.00 | 39.00 | 30.00 | 27.00 | 28.00 | 23.00 | 5.00 |
| Current Liabilities | -43.5% | 80.00 | 142 | 63.00 | 54.00 | 66.00 | 51.00 | 52.00 | 40.00 | 36.00 | 33.00 | 26.00 | 21.00 | 18.00 | 19.00 | 24.00 | 19.00 | 15.00 | 15.00 | 9.00 | 5.00 |
| LT Debt, Current | - | - | - | - | - | - | - | 6.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | 8.1% | 617 | 571 | 511 | 356 | 305 | 268 | 242 | 220 | 208 | 204 | 226 | 237 | 245 | 178 | 193 | 108 | 119 | 129 | - | - |
| Retained Earnings | 1248.4% | 31.00 | 2.00 | -36.81 | -177 | -212 | -238 | -252 | -265 | -267 | -267 | -243 | -227 | -214 | -196 | -177 | -163 | -150 | -139 | -126 | -85.76 |
| Additional Paid-In Capital | 3.1% | 586 | 569 | 549 | 535 | 519 | 507 | 495 | 486 | 476 | 471 | 469 | 465 | 460 | 374 | 371 | 271 | 270 | 269 | 4.00 | 2.00 |
| Shares Outstanding | 0.6% | 37.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | - | - | 35,030 | 34,797 | - | - | 32.00 | 32.00 | 24.00 | 22.00 | 19.00 | 9.00 | 2.00 | 2.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 7.3% | 161 | 150 | 118 | 86.00 | 61.00 | 34.00 | 15.00 | -18.19 | -43.95 | -64.30 | -71.18 | -71.35 | -65.53 | -57.88 | -48.11 | -45.35 | -44.63 | -44.50 | -41.46 | -42.20 | -43.53 |
| Share Based Compensation | 11.8% | 57.00 | 51.00 | 45.00 | 40.00 | 36.00 | 32.00 | 27.00 | 22.00 | 18.00 | 14.00 | 10.00 | 8.00 | 7.00 | 5.00 | 4.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Cashflow From Investing | -313.7% | -118 | -28.55 | -62.15 | -49.98 | -49.48 | -28.08 | 26.00 | -104 | -87.20 | -84.71 | -107 | 63.00 | 58.00 | -54.80 | -59.54 | -77.18 | -85.13 | -2.09 | -0.17 | 1.00 | 2.00 |
| Cashflow From Financing | -102.6% | -2.45 | 94.00 | 13.00 | 4.00 | 6.00 | 3.00 | -2.45 | -1.78 | -2.88 | 83.00 | 90.00 | 185 | 184 | 99.00 | 208 | 131 | 131 | 143 | 30.00 | 14.00 | 21.00 |
SWAV Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Product revenue | $ 180,165 | $ 120,746 | $ 341,231 | $ 214,377 |
| Cost of revenue: | ||||
| Cost of product revenue | 24,493 | 16,730 | 45,559 | 29,620 |
| Gross profit | 155,672 | 104,016 | 295,672 | 184,757 |
| Operating expenses: | ||||
| Research and development | 36,829 | 20,760 | 63,800 | 37,779 |
| Sales and marketing | 56,738 | 40,515 | 110,749 | 76,476 |
| General and administrative | 29,731 | 13,165 | 48,935 | 25,554 |
| Total operating expenses | 123,298 | 74,440 | 223,484 | 139,809 |
| Income from operations | 32,374 | 29,576 | 72,188 | 44,948 |
| Loss from equity method investment | (146) | (1,464) | (969) | (1,511) |
| Interest expense | (810) | (304) | (1,446) | (601) |
| Other income (expense), net | 1,586 | (1,473) | 3,968 | (1,783) |
| Net income before taxes | 33,004 | 26,335 | 73,741 | 41,053 |
| Income tax expense | 4,142 | 774 | 5,754 | 971 |
| Net income | 28,862 | 25,561 | 67,987 | 40,082 |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities | (24) | (320) | 481 | (1,135) |
| Adjustment for net gain realized and included in other income | 0 | 0 | 5 | 0 |
| Total comprehensive income | $ 28,838 | $ 25,241 | $ 68,463 | $ 38,947 |
| Net income per share | ||||
| Basic (USD per share) | $ 0.79 | $ 0.71 | $ 1.86 | $ 1.12 |
| Diluted (USD per share) | $ 0.76 | $ 0.68 | $ 1.78 | $ 1.06 |
| Denominator: | ||||
| Basic (in shares) | 36,663,327 | 35,825,947 | 36,545,948 | 35,707,301 |
| Diluted (in shares) | 38,226,153 | 37,690,094 | 38,139,948 | 37,690,320 |
| Type of Revenue [Extensible List] | Product [Member] | Product [Member] | Product [Member] | Product [Member] |
| Type of Cost, Good Or Service [Extensible List] | Product [Member] | Product [Member] | Product [Member] | Product [Member] |
SWAV Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | |||
|---|---|---|---|---|---|
| CURRENT ASSETS: | |||||
| Cash and cash equivalents | $ 141,458 | $ 156,586 | [1] | ||
| Short-term investments | 117,131 | 147,907 | [1] | ||
| Accounts receivable, net | 96,562 | 71,366 | [1] | ||
| Inventory | 92,093 | 75,112 | [1] | ||
| Prepaid expenses and other current assets | 9,118 | 8,292 | [1] | ||
| Total current assets | 456,362 | 459,263 | [1] | ||
| Operating lease right-of-use assets | 31,117 | 32,365 | [1] | ||
| Property and equipment, net | 59,803 | 48,152 | [1] | ||
| Equity method investment | 2,543 | 3,512 | [1] | ||
| Intangible assets, net | 94,692 | 0 | |||
| Goodwill | 39,789 | 0 | |||
| Deferred tax assets | 94,699 | 97,568 | |||
| Other assets | 7,599 | 5,229 | [1] | ||
| TOTAL ASSETS | 786,604 | 646,089 | [1] | ||
| CURRENT LIABILITIES: | |||||
| Accounts payable | 12,869 | 6,721 | [1] | ||
| Accrued liabilities | 65,769 | 55,375 | [1] | ||
| Lease liability, current portion | 1,582 | 1,278 | [1] | ||
| Total current liabilities | 80,220 | 63,374 | [1] | ||
| Lease liability, noncurrent portion | 33,205 | 34,928 | [1] | ||
| Debt, noncurrent portion | 24,266 | 24,198 | [1] | ||
| Related party contract liability, noncurrent portion | 12,273 | 12,273 | [1] | ||
| Deferred tax liabilities | 10,421 | 0 | |||
| Other liabilities | 9,307 | 0 | |||
| TOTAL LIABILITIES | 169,692 | 134,773 | [1] | ||
| STOCKHOLDERS’ EQUITY: | |||||
| Preferred stock | 0 | 0 | [1] | ||
| Common stock | 37 | 36 | [1] | ||
| Additional paid-in capital | 586,092 | 548,960 | [1] | ||
| Accumulated other comprehensive loss | (391) | (867) | [1] | ||
| Retained earnings (accumulated deficit) | 31,174 | (36,813) | [1] | ||
| TOTAL STOCKHOLDERS’ EQUITY | 616,912 | 511,316 | [1] | ||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 786,604 | $ 646,089 | [1] | ||
| |||||
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.